Nanobiotix and J&J Announce Positive Phase 2 Data for JNJ-1900 (NBTXR3) in Stage 3 Inoperable NSCLC

On May 17, 2026, Nanobiotix S.A. announced positive Part 1 data from the CONVERGE study, a randomized Phase 2 clinical trial evaluating the radioenhancer JNJ-1900 (NBTXR3) in patients with stage 3 inoperable non-small cell lung cancer (NSCLC). The data, presented by partner Johnson & Johnson at the ESTRO 2026 Annual Meeting, demonstrated that intratumoral injection of JNJ-1900 was feasible and safe. Among seven patients who received the full treatment regimen (concurrent chemoradiotherapy, JNJ-1900, and consolidation durvalumab), the overall response rate (ORR) was 85.7% (6/7 patients) and the complete response rate (CRR) was 57.1% (4/7 patients). This CRR is notably higher than the historical standard of care rate of less than 5%. The disease control rate (DCR) reached 100%, with no progressive disease observed. JNJ-1900 is a functionalized hafnium oxide nanoparticle designed to enhance radiotherapy's local effect and trigger an adaptive immune response. The company is also evaluating NBTXR3 in a global Phase 3 study for head and neck cancers.